ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.35% Direct Plan: 0.47%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 17 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	235.68
AAUM (in Rs. Cr):	233.20
% of top 5 holdings:	36.04%
% of top 10 holdings:	54.43%
No. of scrips:	45

Standard Deviation^:	15.16%
Beta^:	0.89
*Sharpe Ratio^:**	1.10
Average P/B	10.11
Average P/E	51.64
Portfolio Turnover Ratio	0.59
^Computed for the 3-yr period ended July 31, 2025. Based on monthly return. * Risk free rate: 5.54 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	16.7605	18.0797
IDCW:	16.7605	18.0797

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	98.71
Capital Goods	0.84
Standard Glass Lining Technology Ltd	0.84
Chemicals	5.29
Sumitomo Chemical India Limited	1.71
Navin Fluorine International Limited	1.05
SRF Limited	0.97
Linde India Limited	0.87
UPL Limited	0.69
Diversified	0.31
TTK Healthcare Limited	0.31
Financial Services	0.73
SBI Life Insurance Company Limited	0.73
Healthcare	90.27
Sun Pharmaceutical Industries Limited	10.93
Divi's Laboratories Limited	8.68
Max Healthcare Institute Limited	6.12
Apollo Hospitals Enterprise Limited	5.66
Cohance Lifesciences Limited	4.66
Torrent Pharmaceuticals Limited	4.58
Aurobindo Pharma Limited	3.66
Fortis Healthcare Limited	3.51
Lupin Limited	3.46
Aster DM Healthcare Limited	3.19
Mankind Pharma Limited	2.97
Wockhardt Limited	2.76
Alkem Laboratories Limited	2.66
Abbott India Limited	2.47
Neuland Laboratories Limited	2.24
Healthcare Global Enterprises Limited	1.66
Vijaya Diagnostic Centre Limited	1.56
FDC Limited	1.44
Granules India Limited	1.38
Laurus Labs Limited	1.31
Rainbow Childrens Medicare Limited	1.30
Dr. Reddy's Laboratories Limited	1.16
Orchid Pharma Limited	1.14
Shilpa Medicare Limited	1.13
GlaxoSmithKline Pharmaceuticals Limited	1.06
Onesource Specialty Pharma Limited	1.05
Supriya Lifescience Limited	1.03
Strides Pharma Science Limited	1.02
Cipla Limited	1.02
IPCA Laboratories Limited	0.98
Caplin Point Laboratories Limited	0.97
Sai Life Sciences Limited	0.77
Advanced Enzyme Technologies Limited	0.76
Biocon Limited	0.74
Glenmark Pharmaceuticals Limited	0.72
Syngene International Limited	0.52
Information Technology	1.27
Sagility India Limited	1.27
Short Term Debt & Net Current Assets	1.29

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	7.23%	9.00%	0.54%	10,723	10,900	10,054
Last 3 Years	22.13%	23.74%	14.29%	18,245	18,977	14,946
Since Inception	14.86%	16.55%	10.15%	16,761	17,701	14,340
Direct - Growth
Last 1 Year	9.25%	9.00%	0.54%	10,925	10,900	10,054
Last 3 Years	24.54%	23.74%	14.29%	19,351	18,977	14,946
Since Inception	17.21%	16.55%	10.15%	18,080	17,701	14,340

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. The performance data for 5 years period has not been provided, since scheme is in existence for less than 5 years. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10.ITI Pharma & Healthcare Fund NAV as on July 31, 2025: Rs. 16.7605 (Regular Growth Option), Rs. 18.0797 (Direct Growth Option)

Period	Amount Invested	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Fund Value ()	Benchmark Value ()	Additional Benchmark Value ()
Regular - Growth
Last 1 Year	1,20,000	6.72%	12.03%	5.66%	1,24,278	1,27,604	1,23,612
Last 3 Years	3,60,000	22.93%	25.44%	13.10%	5,02,525	5,20,105	4,37,497
Since Inception	4,50,000	21.01%	23.04%	13.00%	6,62,035	6,86,030	5,73,520
Direct - Growth
Last 1 Year	1,20,000	8.70%	12.03%	5.66%	1,25,522	1,27,604	1,23,612
Last3 Years	3,60,000	25.36%	25.44%	13.10%	5,19,527	5,20,105	4,37,497
Since Inception	4,50,000	23.39%	23.04%	13.00%	6,90,292	6,86,030	5,73,520

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).